drugset / Trial / NCT00986609

MUC1 Vaccine for Triple-negative Breast Cancer

NCT00986609

Phase 0 Completed 29 enrolled Joseph Baar, MD, PhD
NaSingle-groupOpen-labelOther

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer. PURPOSE: To evaluate the efficacy of poly-ICLC + MUCI peptide vaccine in boosting the immunologic response to MUCI in patients with triple-negative BC

Timeline

Start
2009-08-19
Primary completion
2013-08-29
Completion
2016-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified Intramuscular
Subject MUC1 peptide Vaccine Subcutaneous